Elicio Therapeutics, Inc.
ELTX
$2.18
-$0.17-7.23%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 30.71% | 21.64% | 23.75% | 2.10% | -41.24% |
| Total Depreciation and Amortization | -1.13% | -2.32% | -4.24% | -1.04% | 1.05% |
| Total Amortization of Deferred Charges | 181.82% | 127.27% | 189.33% | -- | -- |
| Total Other Non-Cash Items | -62.25% | -2.79% | -20.86% | 11.43% | 5,380.86% |
| Change in Net Operating Assets | -174.10% | -180.45% | -187.02% | 11.51% | 187.57% |
| Cash from Operations | -7.43% | -9.73% | 0.31% | -1.78% | 2.89% |
| Capital Expenditure | 64.44% | 81.61% | 81.61% | -7.14% | 48.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 64.44% | 81.61% | 80.95% | -15.38% | 46.43% |
| Total Debt Issued | -100.00% | -49.99% | -49.99% | -49.99% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 58.87% | 13.55% | 19.82% | -22.80% | 36.40% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 37.89% | -75.05% | -63.93% | -64.53% | -72,550.00% |
| Cash from Financing | -26.80% | -17.37% | -13.29% | -34.70% | 189.34% |
| Foreign Exchange rate Adjustments | -133.33% | -58.49% | 118.18% | 3,520.00% | 530.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -93.40% | -162.49% | -104.33% | -161.98% | 202.38% |